News Search Results
Oct 07, 2025, 08:33 ET Biotech and Veterinary Innovators Dr. Misti Ushio and Doug Drew Join Gallant Board of Directors
Gallant, an animal health biotechnology company pioneering ready-to-use stem cell therapies for pets, today announced the addition of Misti Ushio, PhD, and Doug Drew, MBA, to its Board
More news about: Gallant
Oct 07, 2025, 08:33 ET Marshall Gerstein Celebrates 70 Years of Intellectual Property Leadership
research institutions, universities, and entrepreneurs. Recognized by Chambers and Partners as "first-rate for litigation" and "one of the best biotechnology practices in the country," the firm is consistently ranked among the nation's top IP practices by Corporate Counsel, Managing Intellectual
More news about: Marshall Gerstein
Oct 07, 2025, 08:30 ET Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of the final patient visit in its breast cancer vaccine
More news about: Anixa Biosciences, Inc.
Oct 07, 2025, 08:30 ET Overcoming Regulatory Hurdles in AAV Production, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 07, 2025, 08:30 ET Boosting clinical trial success in Alzheimer's, Parkinson's and other neurodegenerative diseases, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 07, 2025, 08:30 ET Precision in Pharma Labeling: Avoiding Recalls, Reprints and Compliance Warnings, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 07, 2025, 08:30 ET The Value Proposition of Specialty CROs, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 07, 2025, 08:13 ET US-Manufactured High Performance Linear Positioning Stage Family with Absolute Encoder and Excellent Guiding Precision
automation, device assembly, and laser micro-processing. High-speed pick-and-place, alignment of optics, micromechanics, and photonics components. Biotechnology, microscopy, medical device manufacturing. Specifications, datasheet:
More news about: PI (Physik Instrumente) LP
Oct 07, 2025, 08:00 ET TIE 2025: MOEA DoIT to Demonstrate AI Innovations with Eye-Catching Tech Waterfall Taking Center Stage
cancer include surgery, radiation therapy, and chemotherapy, with limited efficacy and frequent severe side effects. The Development Center for Biotechnology (DCB) and the National Health Research Institutes (NHRI) have developed a novel therapeutic tool for head and neck cancer treatment "NTSR1-ADC"
More news about: Taiwan Innotech Expo
Oct 07, 2025, 08:00 ET RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases
Sciences Investor and Partnering Conference." About RheumaGen, Inc.RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure common autoimmune diseases. RheumaGen focuses on editing the human leukocyte antigen (HLA),
More news about: RheumaGen, Inc.
Oct 07, 2025, 07:30 ET Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Oct 07, 2025, 07:00 ET TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congress
LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- TORL BioTherapeutics LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, today announced
More news about: TORL Biotherapeutics LLC
Oct 07, 2025, 07:00 ET Lilly and Leading Alzheimer's Disease Experts Call for Urgent Action to Close Diagnostic Gaps at Alzheimer Europe Conference
pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: ELI LILLY & COMPANY
Oct 07, 2025, 07:00 ET Lilly and Leading Alzheimer's Disease Experts Call for Urgent Action to Close Diagnostic Gaps at Alzheimer Europe Conference
pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: ELI LILLY & COMPANY
Oct 07, 2025, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 07, 2025, 06:00 ET Invisible Wounds Foundation Names Nationally Recognized Brain Health Experts to its Board of Directors, Medical and Science Advisory Council
Dr. Dallas C. Hack is a trauma research and development consultant who has worked with numerous non-profit organizations and biotechnology firms to advance clinical care for trauma and brain health. As an author of the 2013 National Research Action Plan and the former director of the
More news about: Invisible Wounds Foundation
Oct 07, 2025, 03:30 ET Optimum Strategic Communications to Host 17th Annual Healthcare Investor Conference
exciting public and private companies, both large and small, across pharmaceuticals, biotech, medtech, health tech, healthcare services and industrial biotechnology. Our team has worked with over 400 healthcare companies, advising them on financial communications and investor relations,
More news about: Optimum Strategic Communications
Oct 07, 2025, 03:00 ET Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC
Bracco family of companies. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start–up experience, the company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics
Oct 07, 2025, 03:00 ET Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC
Bracco family of companies. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start–up experience, the company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics
Oct 06, 2025, 20:50 ET AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Oct 06, 2025, 19:10 ET Robbins LLP Reminds Jasper Therapeutics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against JSPR
or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Robbins LLP
Oct 06, 2025, 17:31 ET Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
Bioscience, Yake Biotechnology, Equillium, Daiichi Sankyo Company, SinoMab Bioscience Ltd, Citryll BV, Sareum, Shanghai Junshi Biosciences, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Millennium Pharmaceuticals, Inc., Takeda, Synthekine, Hangzhou Sumgen Biotech Co., Ltd., Sana Biotechnology, Hoffmann-La
More news about: DelveInsight Business Research, LLP
Oct 06, 2025, 17:14 ET ESSA Securityholders Approve Acquisition by XenoTherapeutics
of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") by XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Securityholders held today
More news about: ESSA Pharma Inc
Oct 06, 2025, 16:30 ET Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
LinkedIn. 5. About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Oct 06, 2025, 12:52 ET RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01
www.roosterbio.com About Secretome TherapeuticsSecretome Therapeutics is a clinical-stage biotechnology company developing novel regenerative medicines derived from neonatal cardiac progenitor cells (nCPC) for serious diseases with high unmet need.
More news about: RoosterBio, Inc.